Is tumor bed boost necessary in patients who achieved ypCR following neoadjuvant chemotherapy and breast conserving therapy? (KROG 12-05 and 16-16)

Won Kyung Cho, Won Park, Doo Ho Choi, Yongbae Kim, Chang-Ok Suh, Kyung Hwan Shin, Eui Kyu Chie, Jin Ho Kim, Seung Do Ahn, Su Ssan Kim, Kyubo Kim, Jin Hee Kim, Sung Ja Ahn, Sun Young Lee, Jeongshim Lee, Sang Won Kim, Jeanny Kwon, Ki Jung Ahn, Hyun Soo Shin, Hyung Sik LeeNam Kwon Lee

Research output: Contribution to journalArticle

Abstract

Purpose: This multi-institutional study intended to investigate the effect of tumor bed boost in patients who achieved pathologic complete response (ypCR) following neoadjuvant chemotherapy (NAC) and breast-conserving therapy (BCT). Materials and methods: We identified 180 patients who initially had lymph node (LN) metastasis and achieved ypCR (ypT0/isN0) following NAC and BCT from the 13 institutions of the Korean Radiation Oncology Group (KROG) 16-16 and KROG 12-05. The effect of tumor bed boost on loco-regional control (LRC), disease-free survival (DFS), and overall survival (OS) rates was analyzed. Results: In all patients, five-year LRC, DFS and OS rates were 97.5%, 95.4%, and 99.4%, respectively. Tumor bed boost was performed in 158 (87.8%) patients. Advanced N-stage (cN2-3, p = 0.036), close resection margin (p < 0.001), and sentinel lymph node biopsy (p = 0.040) were unfavorable factors for DFS. Tumor bed boost was not a significant factor for LRC, DFS, and OS. Conclusions: This study suggests the benefit of tumor bed boost might be minimal in ypCR patients following NAC and BCT. Larger prospective studies are needed to address this issue.

Original languageEnglish
Pages (from-to)43-47
Number of pages5
JournalBreast
Volume45
DOIs
Publication statusPublished - 2019 Jun 1

Fingerprint

Radiation Oncology
Breast
Disease-Free Survival
Drug Therapy
Neoplasms
Survival Rate
Therapeutics
Sentinel Lymph Node Biopsy
Lymph Nodes
Prospective Studies
Neoplasm Metastasis
Survival

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Cho, Won Kyung ; Park, Won ; Choi, Doo Ho ; Kim, Yongbae ; Suh, Chang-Ok ; Shin, Kyung Hwan ; Chie, Eui Kyu ; Kim, Jin Ho ; Ahn, Seung Do ; Kim, Su Ssan ; Kim, Kyubo ; Kim, Jin Hee ; Ahn, Sung Ja ; Lee, Sun Young ; Lee, Jeongshim ; Kim, Sang Won ; Kwon, Jeanny ; Ahn, Ki Jung ; Shin, Hyun Soo ; Lee, Hyung Sik ; Lee, Nam Kwon. / Is tumor bed boost necessary in patients who achieved ypCR following neoadjuvant chemotherapy and breast conserving therapy? (KROG 12-05 and 16-16). In: Breast. 2019 ; Vol. 45. pp. 43-47.
@article{a406ab18cd1e4c31aac3196eb5d80a43,
title = "Is tumor bed boost necessary in patients who achieved ypCR following neoadjuvant chemotherapy and breast conserving therapy? (KROG 12-05 and 16-16)",
abstract = "Purpose: This multi-institutional study intended to investigate the effect of tumor bed boost in patients who achieved pathologic complete response (ypCR) following neoadjuvant chemotherapy (NAC) and breast-conserving therapy (BCT). Materials and methods: We identified 180 patients who initially had lymph node (LN) metastasis and achieved ypCR (ypT0/isN0) following NAC and BCT from the 13 institutions of the Korean Radiation Oncology Group (KROG) 16-16 and KROG 12-05. The effect of tumor bed boost on loco-regional control (LRC), disease-free survival (DFS), and overall survival (OS) rates was analyzed. Results: In all patients, five-year LRC, DFS and OS rates were 97.5{\%}, 95.4{\%}, and 99.4{\%}, respectively. Tumor bed boost was performed in 158 (87.8{\%}) patients. Advanced N-stage (cN2-3, p = 0.036), close resection margin (p < 0.001), and sentinel lymph node biopsy (p = 0.040) were unfavorable factors for DFS. Tumor bed boost was not a significant factor for LRC, DFS, and OS. Conclusions: This study suggests the benefit of tumor bed boost might be minimal in ypCR patients following NAC and BCT. Larger prospective studies are needed to address this issue.",
author = "Cho, {Won Kyung} and Won Park and Choi, {Doo Ho} and Yongbae Kim and Chang-Ok Suh and Shin, {Kyung Hwan} and Chie, {Eui Kyu} and Kim, {Jin Ho} and Ahn, {Seung Do} and Kim, {Su Ssan} and Kyubo Kim and Kim, {Jin Hee} and Ahn, {Sung Ja} and Lee, {Sun Young} and Jeongshim Lee and Kim, {Sang Won} and Jeanny Kwon and Ahn, {Ki Jung} and Shin, {Hyun Soo} and Lee, {Hyung Sik} and Lee, {Nam Kwon}",
year = "2019",
month = "6",
day = "1",
doi = "10.1016/j.breast.2019.02.010",
language = "English",
volume = "45",
pages = "43--47",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",

}

Cho, WK, Park, W, Choi, DH, Kim, Y, Suh, C-O, Shin, KH, Chie, EK, Kim, JH, Ahn, SD, Kim, SS, Kim, K, Kim, JH, Ahn, SJ, Lee, SY, Lee, J, Kim, SW, Kwon, J, Ahn, KJ, Shin, HS, Lee, HS & Lee, NK 2019, 'Is tumor bed boost necessary in patients who achieved ypCR following neoadjuvant chemotherapy and breast conserving therapy? (KROG 12-05 and 16-16)', Breast, vol. 45, pp. 43-47. https://doi.org/10.1016/j.breast.2019.02.010

Is tumor bed boost necessary in patients who achieved ypCR following neoadjuvant chemotherapy and breast conserving therapy? (KROG 12-05 and 16-16). / Cho, Won Kyung; Park, Won; Choi, Doo Ho; Kim, Yongbae; Suh, Chang-Ok; Shin, Kyung Hwan; Chie, Eui Kyu; Kim, Jin Ho; Ahn, Seung Do; Kim, Su Ssan; Kim, Kyubo; Kim, Jin Hee; Ahn, Sung Ja; Lee, Sun Young; Lee, Jeongshim; Kim, Sang Won; Kwon, Jeanny; Ahn, Ki Jung; Shin, Hyun Soo; Lee, Hyung Sik; Lee, Nam Kwon.

In: Breast, Vol. 45, 01.06.2019, p. 43-47.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Is tumor bed boost necessary in patients who achieved ypCR following neoadjuvant chemotherapy and breast conserving therapy? (KROG 12-05 and 16-16)

AU - Cho, Won Kyung

AU - Park, Won

AU - Choi, Doo Ho

AU - Kim, Yongbae

AU - Suh, Chang-Ok

AU - Shin, Kyung Hwan

AU - Chie, Eui Kyu

AU - Kim, Jin Ho

AU - Ahn, Seung Do

AU - Kim, Su Ssan

AU - Kim, Kyubo

AU - Kim, Jin Hee

AU - Ahn, Sung Ja

AU - Lee, Sun Young

AU - Lee, Jeongshim

AU - Kim, Sang Won

AU - Kwon, Jeanny

AU - Ahn, Ki Jung

AU - Shin, Hyun Soo

AU - Lee, Hyung Sik

AU - Lee, Nam Kwon

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Purpose: This multi-institutional study intended to investigate the effect of tumor bed boost in patients who achieved pathologic complete response (ypCR) following neoadjuvant chemotherapy (NAC) and breast-conserving therapy (BCT). Materials and methods: We identified 180 patients who initially had lymph node (LN) metastasis and achieved ypCR (ypT0/isN0) following NAC and BCT from the 13 institutions of the Korean Radiation Oncology Group (KROG) 16-16 and KROG 12-05. The effect of tumor bed boost on loco-regional control (LRC), disease-free survival (DFS), and overall survival (OS) rates was analyzed. Results: In all patients, five-year LRC, DFS and OS rates were 97.5%, 95.4%, and 99.4%, respectively. Tumor bed boost was performed in 158 (87.8%) patients. Advanced N-stage (cN2-3, p = 0.036), close resection margin (p < 0.001), and sentinel lymph node biopsy (p = 0.040) were unfavorable factors for DFS. Tumor bed boost was not a significant factor for LRC, DFS, and OS. Conclusions: This study suggests the benefit of tumor bed boost might be minimal in ypCR patients following NAC and BCT. Larger prospective studies are needed to address this issue.

AB - Purpose: This multi-institutional study intended to investigate the effect of tumor bed boost in patients who achieved pathologic complete response (ypCR) following neoadjuvant chemotherapy (NAC) and breast-conserving therapy (BCT). Materials and methods: We identified 180 patients who initially had lymph node (LN) metastasis and achieved ypCR (ypT0/isN0) following NAC and BCT from the 13 institutions of the Korean Radiation Oncology Group (KROG) 16-16 and KROG 12-05. The effect of tumor bed boost on loco-regional control (LRC), disease-free survival (DFS), and overall survival (OS) rates was analyzed. Results: In all patients, five-year LRC, DFS and OS rates were 97.5%, 95.4%, and 99.4%, respectively. Tumor bed boost was performed in 158 (87.8%) patients. Advanced N-stage (cN2-3, p = 0.036), close resection margin (p < 0.001), and sentinel lymph node biopsy (p = 0.040) were unfavorable factors for DFS. Tumor bed boost was not a significant factor for LRC, DFS, and OS. Conclusions: This study suggests the benefit of tumor bed boost might be minimal in ypCR patients following NAC and BCT. Larger prospective studies are needed to address this issue.

UR - http://www.scopus.com/inward/record.url?scp=85062715121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062715121&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2019.02.010

DO - 10.1016/j.breast.2019.02.010

M3 - Article

C2 - 30844692

AN - SCOPUS:85062715121

VL - 45

SP - 43

EP - 47

JO - Breast

JF - Breast

SN - 0960-9776

ER -